| (210) | Number of the EPO application | 19732174 |
| (220) | Filing date of the EPO application | 2019.05.30 |
| (80) | EPO patent specification publication (B) | EPB nr. 13/2021, 2021.03.31 |
| (110) | EPO patent number | 3710485 |
| (21) | Number of the application | e 2020 0976 |
| (71) | Name(s) of applicant(s), code of the country | Abbvie Stemcentrx LLC, US; |
| (72) | Name(s) of inventor(s), code of the country | LIU David, US;
GAVRILYUK Julia, US;
SCHAMMEL Alexander, US; |
| (73) | Name(s) of owner(s), code of the country | AbbVie Stemcentrx LLC, US; |
| (54) | Title of the invention | ANTI-SEZ6 ANTIBODY DRUG CONJUGATES AND METHODS OF USE |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07K 16/28 (2006.01.01); A61K 47/68 (2017.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2020.10.31 |
| (30) | Priority | 201862678061 P, 2018.05.30, US |
| (86) | International application | PCT/US2019/034701, 2019.05.30 |
| (87) | International publication | WO 2019/232241, 2019.12.05 |